Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).  

Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. 

BEACON achieved the primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months (VF12) based on independently adjudicated results and met all primary safety endpoints at the prespecified interim analysis.  

As of the 20 October 2026 data cutoff, a total of 39 adults and 10 adolescents were treated in the BEACON trial, and 31 patients had completed the required follow-up period for the VF12 endpoint.  

The study also met all secondary efficacy endpoints, including freedom from inpatient hospitalisation for severe VOCs for at least 12 consecutive months.  

The safety findings observed as of the data cutoff date were consistent with previously reported data from the BEACON study and with the known and intended effects of plerixafor use and the cell collection process, myeloablative conditioning with busulfan, the autologous hematopoietic stem cell transplantation (HSCT) process, and underlying SCD. 

“These positive topline results represent a defining milestone for risto-cel and for Beam’s base editing technology more broadly, bringing us an important step closer to delivering a potentially transformative, one-time treatment for people living with sickle cell disease,” said John Evans, Chief Executive Officer of Beam Therapeutics.  

“For patients with SCD, severe vaso-occlusive crises can be debilitating and life-threatening, making sustained freedom from these events an important clinical outcome. With these results in hand, we are focused on submitting our planned BLA as early as year-end, which has the potential to be the first BLA for a base editing therapy.”